Richardson, TX – May 21, 2026 – The FDA approved IMMGOLIS and IMMGOLIS INTRI on May 15, 2026. These are the first biosimilars of Johnson & Johnson’s Simponi and Simponi Aria. They have been manufactured by Bio-Thera Solutions and marketed in the U.S. by Accord BioPharma. These interchangeable biosimilars offer new options for adults with moderately to severely active rheumatoid arthritis (in combination with methotrexate) and ulcerative colitis.
It is also necessary to note the fact that this process is taking place at a time when health care systems worldwide face the problem of cost management associated with biologic drugs. The Golimumab drug has been successfully used to treat patients suffering from autoimmune conditions for a long time. But its cost has caused serious difficulties for various stakeholders. Analysts hope that IMMGOLIS will help to create some price competition that could lead to lower acquisition prices. The introduction of biosimilars is going to cause some challenges for coders and billers.
The most urgent issue that should be addressed relates to the changes that need to be made for rheumatology and gastroenterology clinics. The FDA designated both as interchangeable. But providers must still navigate distinct HCPCS codes and J-code assignments that typically follow approval. Early adopters anticipate the temporary use of miscellaneous codes during the initial launch phase. This could delay claims processing and create cash flow issues for infusion centers and specialty clinics. Accord has indicated plans for a commercial launch in the fourth quarter of 2026. This gives stakeholders some time to train billing teams and update their electronic health records.
Reimbursement complexities run deeper than simple code changes. Many payers maintain step-edit requirements or prefer the reference product until biosimilar uptake reaches certain thresholds. Some plans may apply the same reimbursement rate initially. While others could implement separate tiers that favor the lower-cost option more aggressively. This patchwork approach often leaves practices caught between clinical decisions and administrative burdens. “We have seen this pattern with previous TNF biosimilars,” noted one billing manager at a large multispecialty group.
The approval raises broader questions about how biosimilars fit into value-based care models. Payers may view IMMGOLIS as a tool to manage specialty drug spend more effectively. This potentially involves tightening prior authorization criteria or shifting more patients toward subcutaneous administration where possible. The promise of greater affordability matters most for patients. Many have faced high copays or coverage gaps with the originator products. And smaller price cuts would still be good for better compliance and better results in treating rheumatoid arthritis and ulcerative colitis.
As the fourth quarter of 2026 approaches, practices will need to find a balance between innovation and reality. IMMGOLIS can bring about a more sustainable price point for biologic therapies. However, it will put the industry under pressure in terms of readiness for change. Those who make smart decisions today can ensure that they benefit from their regulatory success.
About Paymedics
Paymedics is a US-based AI-driven medical billing services company. Our mission is to make things easier for specialty practices and to streamline the process of managing the revenue cycle using our coding expertise and automated claims management. To learn more, please visit https://paymedics.com/.
References
- FDA Announcement https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-first-interchangeable-biosimilars-simponi-and-simponi-aria-golimumab-treat-rheumatoid
- Gavin EJ. FDA Approves First Golimumab Biosimilars from Accord BioPharma https://www.biopharminternational.com/view/fda-approves-first-golimumab-biosimilars-from-accord-biopharma
- FDA Approves Immgolis and Immgolis Intri as First Biosimilars to Golimumab https://www.pharmacytimes.com/view/fda-approves-immgolis-and-immgolis-intri-as-first-biosimilars-to-golimumab-reference-products-for-ra-and-uc